Seo, J., Polster, J., Israelow, B., Corbett-Helaire, K. S. & Martinez, D. R. Challenges for developing broad-based mucosal vaccines for respiratory viruses. Nat. Biotechnol. 42, 1765–1767 (2024).
Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 185, 896–915 e819 (2022).
Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169–184.e113 (2020).
Collier, A. Y. et al. Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Sci. Transl. Med. 14, eabn6150 (2022).
Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci. Immunol. 7, eadd4853 (2022).
Israelow, B. et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci. Immunol. 6, eabl4509 (2021).
Chen, J. et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci. Bull. 67, 1372–1387 (2022).
Le Nouen, C. et al. Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. Cell 185, 4811–4825.e4817 (2022).
Bricker, T. L. et al. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. Cell Rep. 36, 109400 (2021).
McMahan, K. et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature 626, 385–391 (2024).
Lavelle, E. C. & Ward, R. W. Mucosal vaccines—fortifying the frontiers. Nat. Rev. Immunol. 22, 236–250 (2022).
Pulendran, B., Arunachalam, P. S. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454–475 (2021).
Ben-Akiva, E., Chapman, A., Mao, T. & Irvine, D. J. Linking vaccine adjuvant mechanisms of action to function. Sci. Immunol. 10, eado5937 (2025).
De Gregorio, E., Tritto, E. & Rappuoli, R. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38, 2068–2071 (2008).
Lavelle, E. C. & McEntee, C. P. Vaccine adjuvants: tailoring innate recognition to send the right message. Immunity 57, 772–789 (2024).
Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target. Ther. 8, 283 (2023).
Wakabayashi, A., Shimizu, M., Shinya, E. & Takahashi, H. HMGB1 released from intestinal epithelia damaged by cholera toxin adjuvant contributes to activation of mucosal dendritic cells and induction of intestinal cytotoxic T lymphocytes and IgA. Cell Death Dis. 9, 631 (2018).
Meng, S. et al. Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS ONE 6, e19863 (2011).
Xu, L. et al. Intranasal immunization of mice with inactivated virus and mast cell activator C48/80 elicits protective immunity against influenza H1 but not H5. Immunol. Invest. 43, 224–235 (2014).
Qin, T. et al. Mucosal vaccination for influenza protection enhanced by catalytic immune-adjuvant. Adv. Sci. 7, 2000771 (2020).
McLachlan, J. B. et al. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat. Med. 14, 536–541 (2008).
Van Herck, S., Feng, B. & Tang, L. Delivery of STING agonists for adjuvanting subunit vaccines. Adv. Drug Deliv. Rev. 179, 114020 (2021).
Wang, X. et al. STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature 641, 202–210 (2025).
Li, L. et al. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10, 1043–1048 (2014).
Chauveau, L. et al. Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity. EMBO Rep. 22, e52447 (2021).
Liu, Z. et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 32, 269–287 (2022).
Liu, Z. et al. Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD. Cell Rep. Med. 5, 101445 (2024).
Liu, Z. et al. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates. Proc. Natl Acad. Sci. USA 120, e2221713120 (2023).
Li, T. & Chen, Z. J. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J. Exp. Med. 215, 1287–1299 (2018).
Gehrcken, L., Deben, C., Smits, E. & Van Audenaerde, J. R. M. STING agonists and how to reach their full potential in cancer immunotherapy. Adv. Sci. 12, e2500296 (2025).
Zhou, Y. et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 34, 108699 (2021).
Ying, T. et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796–7805 (2014).
Li, K. et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc. Natl Acad. Sci. USA 114, E3119–E3128 (2017).
Cromer, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21, 395–404 (2021).
Pizzolla, A. et al. Resident memory CD8+ T cells in the upper respiratory tract prevent pulmonary influenza virus infection. Sci. Immunol. 2, eaam6970 (2017).
Channappanavar, R. & Perlman, S. Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. J. Clin. Invest. 130, 6204–6213 (2020).
Camell, C. D. et al. Senolytics reduce coronavirus-related mortality in old mice. Science 373, eabe4832 (2021).
Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).
Ye, T. et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature 624, 630–638 (2023).
Wilson-Welder, J. H. et al. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 98, 1278–1316 (2009).
Wang, J., Li, P. & Wu, M. X. Natural STING agonist as an “ideal” adjuvant for cutaneous vaccination. J. Invest. Dermatol. 136, 2183–2191 (2016).
Ge, X. Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538 (2013).
Zeng, L. P. et al. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci. China Life Sci. 60, 1399–1402 (2017).
Liu, M. Q. et al. A SARS-CoV-2-related virus from Malayan pangolin causes lung infection without severe disease in human ACE2-transgenic mice. J. Virol. 97, e0171922 (2023).
Liu, Z. et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct. Target. Ther. 5, 282 (2020).
Liu, Z. et al. An ultrapotent pan-beta-coronavirus lineage B (beta-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Protein Cell 13, 655–675 (2022).
Xing, L. et al. Early fusion intermediate of ACE2-using coronavirus spike acting as an antiviral target. Cell 188, 1297–1314.e1224 (2025).
Wang, Y. et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J. Clin. Invest. 130, 5235–5244 (2020).